Kathleen TYMMS
(Canberra Rheumatology, Australia)
(WriteSource Medical Pty Ltd, Australia)
(OPAL Rheumatology Ltd, Australia)
(OPAL Rheumatology Ltd, Australia)
Yıl: 2021Cilt: 8Sayı: 2ISSN: 2147-9720 / 2148-4279Sayfa Aralığı: 67 - 72İngilizce

7 0
Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
Objective: To assess the impact of anti-citrullinated protein antibody (ACPA) serostatus on response totreatment with either tumor necrosis factor inhibitors (TNFi) or abatacept in patients with rheumatoidarthritis (RA).Methods: Data was obtained from the Optimizing Patient outcomes in Australian RheumatoLogy(OPAL) dataset. Patient data were included in the analysis if they commenced treatment with abatacept or TNFi between 01 August 2006 and 30 June 2017 and had at least 12 months’ follow-up. Theprimary outcome was the mean change in the clinical disease activity index (CDAI) score from baselineto 12 months.Results: A total of 2,052 patients were included of which 1,415 were in the TNFi cohort (n=1,053 ACPApositive) and 637 in the abatacept cohort (n=445 ACPA positive). Patients were predominantly female(75% TNFi; 80% abatacept) with no significant difference in age between cohorts. Patients with ACPApositivity had longer disease duration before commencing treatment in both the TNFi and abataceptcohorts compared to ACPA negative patients. No difference in disease severity was observed in thosewith ACPA negativity compared to those with ACPA positivity. Patients treated with TNFi and abatacept had significantly improved mean change in CDAI after 12 months; ACPA positivity was associatedwith greater response to treatment with abatacept compared to that in patients with ACPA negativity(p=0.011). No difference in response was observed based on ACPA serostatus in patients treated withTNFi (p=0.73).Conclusion: Baseline ACPA positivity was associated with improved clinical response using CDAI outcome measure at 12 months for abatacept but not for TNFi therapies.
DergiAraştırma MakalesiErişime Açık
  • 1. Deane KD, Holers VM. The natural history of rheumatoid arthritis. Clin Ther 2019; 41: 1256- 69.
  • 2. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-77.
  • 3. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68: 1-26.
  • 4. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: Systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-8.
  • 5. Gavrilă B, Ciofu C, Stoica V. Biomarkers in rheumatoid arthritis, what is new? J Med Life 2016; 9: 144-8.
  • 6. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College Of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
  • 7. Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the ample trial. Ann Rheum Dis 2016; 75: 709-14.
  • 8. Gottenberg J, Courvoisier D, Hernandez M, Iannone F, Lie E, Canhão H, et al. Brief report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: Results from the pan-european registry analysis. Arthritis Rheumatol 2016; 68: 1346-52.
  • 9. Huizinga TWJ, Connolly SE, Johnsen A, Zhu J, Furst DE, Bykerk VP, et al. Thu0114 effect of anti-cyclic citrullinated peptide 2 immunoglobulin m serostatus on efficacy outcomes following treatment with abatacept plus methotrexate in the avert trial. Ann Rheum Dis 2015; 74: 234.
  • 10. Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: A us national observational study. J Rheumatol 2018; 45: 32- 9.
  • 11. Alten RA-O, Nusslein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open 2017; 3: e000345.
  • 12. Roberts L, Arnold M, Bird P, Burnet S, De Jager J, Littlejohn G, et al. Optimising patient outcomes in australian rheumatology (opal) - a quality use of medicines initiative (qumi) with >7000 rheumatoid arthritis (ra) patients. Intern Med J 2011; 41: 19.
  • 13. Tymms K, Littlejohn G. Opal: A clinician driven point of care observational data management consortium. Clin Exp Rheumatol 2014; 32: S-150-2.
  • 14. American College of Rheumatology. Clinical disease activity index (cdai) [Internet]. Atlanta, GA: American College of Rheumatology; 2019 [updated 2019; cited 2019 08 July]. Available from: https://www.rheumatology.org/Portals/0/Files/ CDAI%20Form.pdf.
  • 15. Hansen IMJ, Andreasen RA, van Bui Hansen MN, Emamifar A. The reliability of disease activity score in 28 joints-c-reactive protein might be overestimated in a subgroup of rheumatoid arthritis patients, when the score is solely based on subjective parameters: A cross-sectional, exploratory study. J Clin Rheumatol 2017; 23: 102. 16. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase iiib, multinational, prospective, randomized study. Arthritis Rheum 2013; 65: 28-38.
  • 17. Schiff M, Weinblatt M, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from ample trial. Ann Rheum Dis 2014; 73: 86-94.
  • 18. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006; 54: 3799-808.
  • 19. Martins FM, da Silva JAP, Santos MJ, Vieira-Sousa E, Duarte C, Santos H, et al. Das28, cdai and sdai cut-offs do not translate the same information: Results from the rheumatic diseases portuguese register reuma. Pt. Rheumatology 2014; 54: 286-91.
  • 20. Cush JJ. Early rheumatoid arthritis-is there a window of opportunity? J Rheumatol Suppl 2007; 80: 1-7.
  • 21. Nakajima A, Terayama K, Sonobe M, Aoki Y, Takahashi H, Akatsu Y, et al. Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bdmards): Results of 3 to 4 years of follow-up. Mod Rheumatol 2019: 29: 903-9.
  • 22. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51.
  • 23. Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008; 66: 173-8.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.